Kaku K, et al. – Via performing a 28-week, open-label extension of a multicenter, randomized, placebo-controlled, 24-week phase 3 study, experts evaluated the long-term (52-week) efficiency and safety of ipragliflozin in insulin-treated Japanese individuals with type 1 diabetes (T1D) and insufficient glycemic control. Fifty-three (placeboipragliflozin) and 108 (ipragliflozin) individuals finished the open-label extension (treatment period 2), with 24 and 44 people, respectively, receiving dose rises. The researchers found that, among insulin-treated individuals with T1D, treatment with once-daily ipragliflozin 50 mg was safe and effective. In addition, no safety concerns were related to a dose increase to 100 mg.